Clinical Trial Update: Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

View source ↗

Summary

Retrospective study evaluating first-line treatment with avelumab plus axitinib in Japanese renal cell carcinoma patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2023-12-06